Skip to search formSkip to main contentSkip to account menu

panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionHistone DeacetylaseNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (4)

Antineoplastic AgentsHistone deacetylase inhibitorHydroxamic AcidsIndoles

Narrower (1)

LBH589

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Rational design and diversity-oriented synthesis of peptoid-based selective HDAC 6 inhibitors †
Histone deacetylases (HDACs) catalyze the cleavage of acetyl groups from N-acetyl-lysine residues of histones and non-histone… 
2014
2014
Small Molecule Therapeutics BET Protein Antagonist JQ 1 Is Synergistically Lethal with FLT 3 Tyrosine Kinase Inhibitor ( TKI ) and Overcomes Resistance to FLT 3-TKI in AML Cells Expressing FLT-ITD
Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and… 
2010
2010
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
1115 Background: In vivo experiments have demonstrated synergy when the histone deacetylase (HDAC) inhibitors are combined with… 
2010
2010
Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT).
8007 Background: Panobinostat (PAN) is a pan-deacetylase inhibitor targeting epigenetic and non-epigenetic oncogenic pathways. In… 
2010
2010
A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post…
TPS283 Background: Medical treatment options for myelofibrosis (MF) are palliative in nature. Short of allogeneic stem cell… 
2010
2010
Deacetylase inhibitor (DACI) panobinostat in relapsed small cell lung cancer (SCLC) patients: Results of a multicenter phase II trial.
e17521 Background: Panobinostat (P) is a pan deacetylase inhibitor hydroxamic acid derivative, currently in the clinic in several… 
2010
2010
PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).
TPS308 Background: BTZ, a backbone of novel therapy for patients (pts) with MM, is an effective agent but pts will relapse and… 
2010
2010
A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer.
e13089 Background: Panobinostat (PAN; LBH589) has been found to inhibit CYP2D6 in vitro. It was hypothesized that PAN may inhibit… 
2009
2009
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma
Panobinostat is a novel cinnamic hydroxamic acid pan-deacetylase inhibitor able to induce hyperacetylation of lysine residues on… 
2008
2008
Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)